Description | The formulation is from the literature DOI: 10.1073/pnas.2207841119. The special lipids synthesised enable specific targeting of lymph nodes, and the formulation can be used to develop mRNA cancer-targeted vaccines without the need to modify any of the active targeting ligands. Compared with LNPs formulated with ALC-0315, a key component in the US Food and Drug Administration (FDA)-approved Comirnaty, 113-O12B showed significantly reduced mRNA expression in the liver and higher expression in LNs after subcutaneous (SC) injection. |
Lipid composition | 113-O12B/Chol/DOPE/DMG-PEG (16:4.8:3:2.4, mole ratio) |
Product Name | Catalog | Lipid composition | Liposome Size | Price |
---|---|---|---|---|
FA-Lipid Nanoparticles (Targeted to Macrophages) | CDCLP24-001-L | DOTAP/Cholesterol/DSPC/DSPE-PEG2000 (50:38.5:10:1.5, mole ratio) | INQUIRY | |
W-Lipid Nanoparticles (Targeted to Chondrocytes) | CDCLP24-002-L | DOTAP/Cholesterol/DSPC/DSPE-PEG2000 (50:38.5:10:1.5, mole ratio) | INQUIRY | |
FPD-Lipid Nanoparticles | CDCLP24-003-L | SM-102/DSPC/cholesterol/FPD (50:10:38.5:1.5, mole ratio) | INQUIRY | |
DB-Lipid Nanoparticles | CDCLP24-004-L | DB-lipidoids(11-10-8)/DOPE/Cholesterol/DMG-PEG (40:10:48.8:1.5, mole ratio) | INQUIRY | |
4N4T-Lipid Nanoparticles | CDCLP24-005-L | 4N4T lipids/DOPE/Chol/DMG-PEG2K (35:16:46.5:2.5, mole ratio) | INQUIRY | |
C5-Lipid Nanoparticles (Targeted to Placenta) | CDCLP24-006-L | C12-494/DOPE/Chol/Lipid-PEG2K (51.4:14:32.7:1.9, mole ratio) | INQUIRY | |
Sito-Lipid Nanoparticles | CDCLP24-007-L | DLin-MC3-DMA/β-sitosterol/DMG-PEG2K/DSPC (50:36.5:3.5:10, mole ratio) | INQUIRY | |
C10-Lipid Nanoparticles (Targeted to Liver) | CDCLP24-008-L | Ionizable lipid/DOPE/Cholesterol/PEG-lipid (26.5:20:52:1.5, mole ratio) | INQUIRY |